Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
HeartBeam, Inc. (NASDAQ: BEAT) announced its acquisition of LIVMOR’s assets, including the FDA-cleared Halo+™ Atrial Fibrillation Detection System, enhancing its remote monitoring capabilities. The partnership with Evolve Manufacturing aims to develop the HeartBeam AIMIGo 12-Lead electrocardiogram device, with initial market testing slated for Q4 2023 post-FDA clearance. The company received European patents protecting its technology, facilitating expansion. Financial results show a net loss of $3.7 million for Q4 2022, up from $2.1 million a year prior, with cash reserves at $3.6 million. Management projects further advancements in FDA submissions in 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has acquired substantially all assets of LIVMOR, a digital health solutions company, enhancing its capabilities in remote cardiac monitoring. This acquisition includes the FDA-cleared Halo+™ Atrial Fibrillation Detection System, the first prescription wearable for continuous monitoring of cardiac rhythms. Founded in 2016, LIVMOR's technology has been deployed in the VA Healthcare System in Dallas, Texas. The strategic move is expected to integrate LIVMOR's cloud-based software with HeartBeam's existing solutions, potentially improving patient outcomes and reducing healthcare costs. Financial terms remain undisclosed.
HeartBeam, Inc. (NASDAQ: BEAT) announced a senior leadership change with
HeartBeam, Inc. (NASDAQ: BEAT), a company specializing in cardiac technology, will hold a conference call on Thursday, March 16, 2023, at 4:30 p.m. Eastern time to discuss its fourth quarter and full fiscal year results for 2022. The call will cover recent announcements, ongoing initiatives, and key milestones for 2023. Attendees can access the call via a webcast or by dial-in options. A replay will be available until June 16, 2023. HeartBeam has developed a unique 3D-vector ECG platform for heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Robert Eno as President, a newly created role aimed at enhancing the company's strategic and operational capabilities. Eno brings over 28 years of experience in developing markets for innovative medical technologies. He will be instrumental in the strategic direction and commercialization of HeartBeam's AIMI™ and AIMIGo™ platforms, which are designed for remote heart attack detection. HeartBeam, known for its unique 3D-vector ECG platform, seeks to establish itself as a leader in ambulatory cardiology.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
